Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
2.4
Journals
Medicina
Special Issues
Recent Developments in Anticancer Drug Delivery
share announcement

Recent Developments in Anticancer Drug Delivery

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (31 January 2025) | Viewed by 3105

Special Issue Editors

Prof. Dr. Simone Beninati

E-Mail Website
Guest Editor
Department of Biology, University of Tor Vergata, Rome, Italy
Interests: experimental oncology; biochemistry
Special Issues, Collections and Topics in MDPI journals
Dr. Carlo Mischiati

E-Mail Website
Guest Editor
Clinical Biochemistry Laboratory, Department of Neurosciences and Rehabilitation, Faculty of Medicine, Pharmacy and Prevention, University of Ferrara, Via Luigi Borsari 46, Ferrara, Italy
Interests: biochemistry; molecular biology; medical genetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue will bring together recent scientific advances in the field of cancer drug delivery and, in particular, the current challenges facing cancer treatments. Our improved knowledge of carcinogenesis and cell biology has led to an increase in the types of cancer treatment available in recent years. However, many cancers are still fatal, and it has been recognized that the best way to improve the survival rate of cancer patients is through the targeted delivery of anticancer drugs. These new types of formulations are characterized by their suitability for targeted delivery to specific tissues, cells, and even intracellular structures. Targeted delivery allows not only a specific effect but also a reduction in the dosage of the usually very toxic drug. The main objective of this Special Issue is to highlight the potential development of vehicles for the delivery of anticancer drugs, emphasizing the specificity of the sites of action and the possible occurrence of undesirable side effects. We are pleased to invite you to contribute to this Special Issue by submitting original articles and reviews on this topic.

We look forward to receiving your contributions.

Prof. Dr. Simone Beninati
Prof. Dr. Carlo Mischiati
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • anticancer drugs
  • cell-targeted delivery
  • nanocarriers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

10 pages, 1928 KiB  
Article
Targeted Suppression of CEACAM6 via pHLIP-Delivered RNAs in Pancreatic Ductal Adenocarcinoma
by Hongsik Kim, Chang-Gok Woo, Seung-Myoung Son, Yong-Pyo Lee, Hee-Kyung Kim, Yaewon Yang, Jihyun Kwon, Ki-Hyeong Lee, Ho-Chang Lee, Ok-Jun Lee and Hye-Sook Han
Medicina 2025, 61(4), 598; https://doi.org/10.3390/medicina61040598 - 26 Mar 2025
Viewed by 412
Abstract
Background and Objectives: Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is involved in pancreatic cancer progression and is an attractive therapeutic target for pancreatic cancer. In this study, we evaluated the therapeutic efficacy of small-interfering RNA (siRNA) targeting CEACAM6 (siCEACAM6) and the [...] Read more.
Background and Objectives: Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is involved in pancreatic cancer progression and is an attractive therapeutic target for pancreatic cancer. In this study, we evaluated the therapeutic efficacy of small-interfering RNA (siRNA) targeting CEACAM6 (siCEACAM6) and the CEACAM6-suppressive microRNA-29a (miR-29a) in a pancreatic ductal adenocarcinoma xenograft mouse model using pH-low insertion peptide (pHLIP) technology, which targets the acidic tumor microenvironment. Materials and Methods: The delivery vectors for siRNA and miRNA were constructed by conjugating the peptide nucleic acid forms of siCEACAM6 and miR-29a to a peptide with a pHLIP, enabling the transport of siRNA and miRNA across the plasma membrane. The tumor-suppressive effects of pHLIP-siCEACAM6 and pHLIP-miR-29a were assessed in vivo using a BALB/c xenograft mouse model with the injection of the CFPAC-1 human pancreatic ductal adenocarcinoma cell line. Results: The treatment of CFPAC-1 cells with pHLIP-siCEACAM6 and pHLIP-miR-29a under acidic pH conditions suppressed CEACAM6 expression and decreased cell viability. In a xenograft mouse model, the intravenous injection of pHLIP-siCEACAM6 and pHLIP-miR-29a suppressed tumor growth by up to 25.1% (p < 0.01) and 21.2% (p < 0.01), respectively, compared to the control mice treated with pHLIP-scr. Conclusions: Our results demonstrated the efficacy of the pHLIP-mediated delivery of siCEACAM6 and miR-29a as a promising therapeutic strategy in a pancreatic ductal adenocarcinoma xenograft mouse model. The pHLIP technology, which targets the acidic tumor microenvironment, represents an innovative approach to the delivery of small RNAs to pancreatic ductal adenocarcinoma cells, providing new potential strategies for pancreatic cancer treatment. Full article
(This article belongs to the Special Issue Recent Developments in Anticancer Drug Delivery)
►▼ Show Figures

Figure 1

Other

Jump to: Research

9 pages, 1388 KiB  
Case Report
Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression
by Walid Shalata, Ashraf Abu Jama, Yulia Dudnik, Omar Abu Saleh, Sondos Shalata, Lena Tourkey, Kim Sheva, Amichay Meirovitz and Alexander Yakobson
Medicina 2024, 60(8), 1270; https://doi.org/10.3390/medicina60081270 - 6 Aug 2024
Cited by 3 | Viewed by 2262
Abstract
Recent advancements in targeted therapies for non-small-cell lung cancer (NSCLC), specifically focusing on epidermal growth factor receptor (EGFR) mutations, have revolutionized treatment strategies. Osimertinib, an approved therapy for metastatic NSCLC with EGFR mutations, highlights remarkable efficacy but also harbors the potential for severe [...] Read more.
Recent advancements in targeted therapies for non-small-cell lung cancer (NSCLC), specifically focusing on epidermal growth factor receptor (EGFR) mutations, have revolutionized treatment strategies. Osimertinib, an approved therapy for metastatic NSCLC with EGFR mutations, highlights remarkable efficacy but also harbors the potential for severe adverse events, whose rarity or lack of precedence may mask their criticality. This article delves into the exploration of adverse events linked to osimertinib, shedding light on a rare yet life-threatening occurrence: severe myelosuppression. A case study detailing a patient with EGFR-mutated NSCLC exhibiting a robust treatment response but experiencing severe myelosuppression following osimertinib initiation is presented. Immediate discontinuation of osimertinib alongside concurrent blood transfusions facilitated toxicity recovery, prompting a successful reduction in myelosuppression severity upon re-administration at a lowered dosage. Full article
(This article belongs to the Special Issue Recent Developments in Anticancer Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop